NO981962L - (-)Cis-6(S)fenyl-5(R)£4-(2-pyrrolidin-1-yl-etoksy)fenyl|-5,6,7,8,-tertahydronaftalen-2-ol-D-tartrat - Google Patents

(-)Cis-6(S)fenyl-5(R)£4-(2-pyrrolidin-1-yl-etoksy)fenyl|-5,6,7,8,-tertahydronaftalen-2-ol-D-tartrat

Info

Publication number
NO981962L
NO981962L NO981962A NO981962A NO981962L NO 981962 L NO981962 L NO 981962L NO 981962 A NO981962 A NO 981962A NO 981962 A NO981962 A NO 981962A NO 981962 L NO981962 L NO 981962L
Authority
NO
Norway
Prior art keywords
phenyl
tertahydronaftalen
pyrrolidin
tartrate
cis
Prior art date
Application number
NO981962A
Other languages
English (en)
Other versions
NO310358B1 (no
NO981962D0 (no
Inventor
Charles K Chiu
Morgan Meltz
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO981962L publication Critical patent/NO981962L/no
Publication of NO981962D0 publication Critical patent/NO981962D0/no
Publication of NO310358B1 publication Critical patent/NO310358B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19981962A 1995-11-02 1998-04-30 (-)Cis-6(S)-fenyl-5(R)-[4-(2-pyrrolidin-1-yl-etoksy)fenyl]- 5,6,7,8,-tetrahydronaftalen-2-ol-D-tartrat, anvendelse,farmasöytisk blanding og fremstilling derav NO310358B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US612595P 1995-11-02 1995-11-02
PCT/IB1996/001049 WO1997016434A1 (en) 1995-11-02 1996-10-04 (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate

Publications (3)

Publication Number Publication Date
NO981962L true NO981962L (no) 1998-04-30
NO981962D0 NO981962D0 (no) 1998-04-30
NO310358B1 NO310358B1 (no) 2001-06-25

Family

ID=21719433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981962A NO310358B1 (no) 1995-11-02 1998-04-30 (-)Cis-6(S)-fenyl-5(R)-[4-(2-pyrrolidin-1-yl-etoksy)fenyl]- 5,6,7,8,-tetrahydronaftalen-2-ol-D-tartrat, anvendelse,farmasöytisk blanding og fremstilling derav

Country Status (43)

Country Link
US (1) US5948809A (no)
EP (1) EP0876359B1 (no)
JP (1) JP3088020B2 (no)
KR (1) KR19990067280A (no)
CN (1) CN1067065C (no)
AP (1) AP713A (no)
AR (1) AR004078A1 (no)
AT (1) ATE248827T1 (no)
AU (1) AU708841B2 (no)
BG (1) BG63943B1 (no)
BR (1) BR9611436A (no)
CA (1) CA2236673C (no)
CO (1) CO4770967A1 (no)
CZ (1) CZ287341B6 (no)
DE (1) DE69629837T2 (no)
DK (1) DK0876359T3 (no)
DZ (1) DZ2114A1 (no)
EG (1) EG21095A (no)
ES (1) ES2203713T3 (no)
GT (1) GT199600085A (no)
HR (1) HRP960503B1 (no)
HU (1) HU227521B1 (no)
IL (1) IL124027A (no)
IS (1) IS1855B (no)
MA (1) MA23998A1 (no)
NO (1) NO310358B1 (no)
NZ (1) NZ318498A (no)
OA (1) OA11009A (no)
PE (1) PE17698A1 (no)
PL (1) PL188633B1 (no)
PT (1) PT876359E (no)
RO (1) RO119829B1 (no)
RU (1) RU2162465C2 (no)
SI (1) SI0876359T1 (no)
SK (1) SK282172B6 (no)
TN (1) TNSN96134A1 (no)
TR (1) TR199800783T2 (no)
TW (2) TW518327B (no)
UA (1) UA51676C2 (no)
UY (1) UY24362A1 (no)
WO (1) WO1997016434A1 (no)
YU (1) YU49123B (no)
ZA (1) ZA969212B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
JP2002518328A (ja) * 1998-06-16 2002-06-25 ファイザー・プロダクツ・インク 筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
HN1999000097A (es) * 1998-06-16 1999-11-03 Pfizer Prod Inc Terapia de combinacion para la fragilidad muscoloesqueletica
ES2220005T3 (es) * 1998-06-16 2004-12-01 Pfizer Products Inc. Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
AP2002002641A0 (en) 2000-04-07 2002-12-31 Pfizer Prod Inc Estrogen agonist metabolites.
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
GEP20053654B (en) 2001-05-01 2005-11-10 Pfizer Prod Inc Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
EP1411922A1 (en) * 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
RS80604A (sr) * 2002-03-28 2007-02-05 Pfizer Products Inc., Prečišćen lazofoksifen i postupci prečišćavanja lazofoksifena rekristalizacijom
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
JP2008503561A (ja) * 2004-06-21 2008-02-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 骨芽細胞機能を刺激するためのｐｙｋ２阻害薬
BRPI0512245A (pt) * 2004-06-30 2008-02-19 Lilly Co Eli composto, composição farmacêutica, e, uso do composto
ATE482940T1 (de) 2005-06-22 2010-10-15 Pfizer Prod Inc Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)- phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin- hydrochlorid
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
EP2424839A4 (en) 2009-04-29 2012-10-17 Glenmark Generics Ltd PROCESS FOR THE PREPARATION OF LASOFOXIFEN TARTRATE
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025043004A1 (en) 2023-08-21 2025-02-27 Duke University Treatment of solid cancer with lasofoxifene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
HUP9900087A2 (hu) 1999-05-28
IS4718A (is) 1998-04-16
AU708841B2 (en) 1999-08-12
CN1201458A (zh) 1998-12-09
EP0876359B1 (en) 2003-09-03
DE69629837T2 (de) 2004-05-06
AP713A (en) 1998-12-28
DK0876359T3 (da) 2003-11-24
SK282172B6 (sk) 2001-11-06
HRP960503A2 (en) 1998-04-30
CA2236673C (en) 2002-03-19
NO310358B1 (no) 2001-06-25
IL124027A (en) 2001-10-31
EG21095A (en) 2000-10-31
EP0876359A1 (en) 1998-11-11
GT199600085A (es) 1998-04-04
HU227521B1 (en) 2011-07-28
RU2162465C2 (ru) 2001-01-27
NZ318498A (en) 1999-06-29
CA2236673A1 (en) 1997-05-09
SI0876359T1 (en) 2003-12-31
OA11009A (en) 2003-03-03
TNSN96134A1 (fr) 1998-12-31
RO119829B1 (ro) 2005-04-29
UA51676C2 (uk) 2002-12-16
PE17698A1 (es) 1998-04-18
CN1067065C (zh) 2001-06-13
ES2203713T3 (es) 2004-04-16
IS1855B (is) 2003-02-21
HRP960503B1 (en) 2001-12-31
WO1997016434A1 (en) 1997-05-09
ATE248827T1 (de) 2003-09-15
BR9611436A (pt) 1999-03-23
PL326498A1 (en) 1998-09-28
AP9600880A0 (en) 1997-01-31
YU57896A (sh) 1998-12-23
CZ287341B6 (en) 2000-10-11
PL188633B1 (pl) 2005-03-31
AU6998496A (en) 1997-05-22
YU49123B (sh) 2004-03-12
BG102474A (en) 1999-06-30
HUP9900087A3 (en) 1999-11-29
MX9803544A (es) 1998-09-30
SK54298A3 (en) 1999-07-12
ZA969212B (en) 1998-05-04
JP3088020B2 (ja) 2000-09-18
TR199800783T2 (xx) 1998-08-21
CO4770967A1 (es) 1999-04-30
UY24362A1 (es) 1997-04-24
PT876359E (pt) 2003-12-31
TW581766B (en) 2004-04-01
KR19990067280A (ko) 1999-08-16
DE69629837D1 (de) 2003-10-09
JPH11502866A (ja) 1999-03-09
CZ132098A3 (cs) 1999-03-17
AR004078A1 (es) 1998-09-30
BG63943B1 (bg) 2003-07-31
DZ2114A1 (fr) 2002-07-22
NO981962D0 (no) 1998-04-30
TW518327B (en) 2003-01-21
US5948809A (en) 1999-09-07
MA23998A1 (fr) 1997-07-01

Similar Documents

Publication Publication Date Title
NO981962D0 (no) (-)Cis-6(S)fenyl-5(R)£4-(2-pyrrolidin-1-yl-etoksy)fenyl|-5,6,7,8,-tertahydronaftalen-2-ol-D-tartrat
DE69630181D1 (de) Anästhesiegerät
PT907650E (pt) N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
DE69632557D1 (de) Telefonanrufbeantworter
DE69631263D1 (de) Telefonanrufbeantworter
ZA956013B (en) New 1-[4-(aminomethyl)phenyl]-substituted quinolonecarboxylic acids
KR960025961U (ko) 적외선을 이용한 무선 전화기
KR960009847U (ko) 탁상용 거울
KR960016196U (ko) 테이블의 지각 결착구
KR960013530U (ko) 기준블럭이 구비된 공작기계의 테이블
KR960019356U (ko) 무선전화기
KR960003205U (ko) 전화기용 잭
KR950021930U (ko) 자동응답 전화기
ITBS960052A0 (it) Macchina bricchettatrice
KR960038294U (ko) 자동 응답 속도계 센서
KR970026159U (ko) 자동응답 전화기
SE9403584D0 (sv) Databasuppringare med telefonsvarare
KR950034539U (ko) 자동 응답 전화기
IT239978Y1 (it) Tavolino servitore
KR960009848U (ko) 탁상용 거울
SE9303209D0 (sv) Likströmsmaskin
KR960007578U (ko) 버스장착 절첩 회의 테이블
DK58093D0 (da) Cigaretmaskine
KR950017301U (ko) 다용도 프레스기
KR950024050U (ko) 다용도 전화기 받침대

Legal Events

Date Code Title Description
MK1K Patent expired